cdk7 inhibitor gtaexs617
Generic: CDK7 Inhibitor GTAEXS617
cdk7 inhibitor gtaexs617: developed by 1 company · 1 clinical trial tracked.
cdk7 inhibitor gtaexs617 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect cdk7 inhibitor gtaexs617 to RXRX; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could cdk7 inhibitor gtaexs617 → RXRX affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Advanced solid tumors (including ovarian cancer, colorectal cancer, non-small cell lung cancer)
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) Advanced solid tumors (including ovarian cancer, colorectal … | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Interventionalopen230 targetStarted 2023-07Completion 2028-0515 sites · Belgium, United Kingdom, United StatesExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Frequently asked questions
Who is developing cdk7 inhibitor gtaexs617?
cdk7 inhibitor gtaexs617 is being developed by RECURSION PHARMACEUTICALS, INC..
How many clinical trials involve cdk7 inhibitor gtaexs617?
BioSniper tracks 1 clinical trial involving cdk7 inhibitor gtaexs617.